Immuto Scientific Health false
3 known investors
Immuto Scientific uses patient-derived tissue models combined with computational structural proteomics and machine learning to identify disease-specific protein targets for drug discovery. The platform applies advanced mass spectrometry and molecular simulations to distinguish diseased from healthy tissues and accelerate therapeutic development.
Founders & leadership
Investors · 3
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $321.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Immuto Scientific Health false do?
- Immuto Scientific uses patient-derived tissue models combined with computational structural proteomics and machine learning to identify disease-specific protein targets for drug discovery. The platform applies advanced mass spectrometry and molecular simulations to distinguish diseased from healthy tissues and accelerate therapeutic development.
- Who founded Immuto Scientific Health false?
- Immuto Scientific Health false was founded by Faraz A Choudhury, Daniel Benjamin.
- Who are Immuto Scientific Health false's investors?
- Immuto Scientific Health false's investors include DYDX Capital, Great Oaks Venture Capital, Tundra Angels.